BioSoteria Senior Vice President to Present at the 47th Annual DIA Conference.

Share Article

BioSoteria Senior Vice President of Pharmacovigilance and Risk Management, James Buchanan, PharmD, will present "Signal Detection: MedDRA® and Other Key Issues" at the 47th Annual DIA Conference in Chicago, Illinois from June 19 – 23, 2011.

News Image

James Buchanan, PharmD, Senior Vice President, Pharmacovigilance and Risk Management, Biosoteria, Inc.

BioSoteria, Inc., Drug Safety and Risk Management Specialists, announced today that its Senior Vice President, James Buchanan, PharmD, will present "Signal Detection: MedDRA® and Other Key Issues." Dr. Buchanan will cover methods for identifying safety signals, in both clinical development and post-marketing settings, and how MedDRA® can facilitate the identification of these safety signals. The discussion will include the importance of consistently applying a standardized nomenclature, how groupings of medically relevant terms can facilitate case identification and how such cases are further reviewed to identify safety signals for evaluation. A number of tools available to aid signal detection will be discussed. Finally, a framework will be presented to assist companies to construct a signal detection strategy for their products in clinical development and post-marketing.

His presentation will take place at the 47th Annual DIA Conference in Chicago, Illinois at the MedDRA® user group meeting on Thursday, June 23, 2011 at McCormick Place, Meeting Room Number: West 185 BC from 3:15-4:15PM.

To find out more about the DIA Conference please go to

About BioSoteria
Founded in 2007 with a strong vision of a progressive drug safety and pharmacovigilance consulting services and education, BioSoteria serves the outsourcing needs of the pharmaceutical industry. From strategic risk management consulting services and full-service drug safety operational capabilities to world-class award winning pharmacovigilance training and education programs, BioSoteria provides unmatched experience, expertise, and leadership to support your company’s efforts to maximize your product’s benefit-risk profile. For more information and to learn more about BioSoteria’s drug safety services and training programs, go to


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Les Williams
BioSoteria, Inc.
(866) 660-5553 x 22
Email >
Visit website